• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过直接压片法制备并评价含速尿的口腔崩解片。

Preparation and evaluation of furosemide containing orally disintegrating tablets by direct compression.

作者信息

Gulsun T, Ozturk N, Kaynak M S, Vural I, Sahin S

出版信息

Pharmazie. 2017 Jul 3;72(7):389-394. doi: 10.1691/ph.2017.6149.

DOI:10.1691/ph.2017.6149
PMID:29441935
Abstract

The purpose of this research was to develop and prepare orally disintegrating tablets (ODTs) containing furosemide by direct compression method. Furosemide, microcrystalline cellulose (MCC), low-substituted hydroxypropylcellulose LH-11 (L-HPC), aspartame, sodium stearyl fumarate were used for ODT formulation. MCC and L-HPC were used in ratios of 1:9 (ODT1) and 1:4 (ODT2). The results of the quality control parameters obtained for bulk powders (angle of repose, compressibility index, Hausner ratio, bulk density and volume, apparent density and volume, swelling of superdisintegrants and powder moisture) were taken as an indication of good compressibility of tablets. Both ODT1 and ODT2 disintegrated within 15 s and fulfilled the required disintegration time given by the European Pharmacopoeia (3 min). The average weight variation was less than 5% for both tablets. The friability of the tablets was less than 1%. Wetting time of both tablets was in the range of 12-21.7 s. Water absorption ratio was 1.41±0.03 for ODT1 and 1.96±0.10 for ODT2. Dissolution studies revealed that more than 85% of furosemide was dissolved in 15 min from both ODTs. Based on cell culture studies, permeability of furosemide was low (Papp=1x10-5 cm/s) but increased when prepared in the ODT form (ODT1: Papp=2x10-5 cm/s; ODT2: Papp=3.6x10-5 cm/s). Collectively, all these results showed that ODT formulations of furosemide were developed successfully. To improve patient compliance, ODT approach can be suggested for development and manufacturing of furosemide ODTs.

摘要

本研究的目的是通过直接压片法研制并制备含呋塞米的口腔崩解片(ODT)。将呋塞米、微晶纤维素(MCC)、低取代羟丙基纤维素LH - 11(L - HPC)、阿斯巴甜、硬脂酰富马酸钠用于ODT制剂。MCC和L - HPC的使用比例分别为1:9(ODT1)和1:4(ODT2)。对原料药获得的质量控制参数(休止角、压缩性指数、豪斯纳比、堆密度和体积、表观密度和体积、超级崩解剂的溶胀和粉末水分)结果被视为片剂良好可压性的指标。ODT1和ODT2均在15秒内崩解,并符合欧洲药典规定的所需崩解时间(3分钟)。两种片剂的平均重量差异均小于5%。片剂的脆碎度小于1%。两种片剂的润湿时间在12 - 21.7秒范围内。ODT1的吸水率为1.41±0.03,ODT2为1.96±0.10。溶出度研究表明,两种ODT在15分钟内呋塞米的溶出量均超过85%。基于细胞培养研究,呋塞米的渗透率较低(Papp = 1×10 - 5 cm/s),但制成ODT形式时有所增加(ODT1:Papp = 2×10 - 5 cm/s;ODT2:Papp = 3.6×10 - 5 cm/s)。总体而言,所有这些结果表明呋塞米的ODT制剂研制成功。为提高患者依从性,可建议采用ODT方法来研发和生产呋塞米ODT。

相似文献

1
Preparation and evaluation of furosemide containing orally disintegrating tablets by direct compression.通过直接压片法制备并评价含速尿的口腔崩解片。
Pharmazie. 2017 Jul 3;72(7):389-394. doi: 10.1691/ph.2017.6149.
2
Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets.盐酸二甲双胍和格列吡嗪口腔崩解片的研制与评价。
Pharm Dev Technol. 2020 Oct;25(8):999-1009. doi: 10.1080/10837450.2020.1772290. Epub 2020 Jun 11.
3
Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression.直接压片法制备氯氮平口腔崩解片的处方设计与评价
Pharmazie. 2013 Feb;68(2):110-6.
4
Evaluation of hot-melt extrusion and injection molding for continuous manufacturing of immediate-release tablets.热熔挤出和注塑成型用于速释片连续制造的评估
J Pharm Sci. 2015 Jun;104(6):1971-1980. doi: 10.1002/jps.24419. Epub 2015 Mar 11.
5
A novel and discriminative method of in vitro disintegration time for preparation and optimization of taste-masked orally disintegrating tablets of carbinoxamine maleate.一种新颖且具有区分度的体外崩解时间方法,用于马来酸卡比沙明掩味口腔崩解片的制备和优化。
Drug Dev Ind Pharm. 2018 Aug;44(8):1317-1327. doi: 10.1080/03639045.2018.1449854. Epub 2018 Mar 22.
6
Formulation studies for mirtazapine orally disintegrating tablets.米氮平口腔崩解片的处方研究
Drug Dev Ind Pharm. 2016;42(6):1008-17. doi: 10.3109/03639045.2015.1104345. Epub 2015 Nov 4.
7
Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.采用共处理赋形剂的巴氯芬-美洛昔康口崩片(ODTs)的配方和评价以及使用六西格玛方法改善 ODTs 性能。
Drug Des Devel Ther. 2021 Oct 16;15:4383-4402. doi: 10.2147/DDDT.S327193. eCollection 2021.
8
Evaluation about wettability, water absorption or swelling of excipients through various methods and the correlation between these parameters and tablet disintegration.评估辅料的润湿性、吸水性或溶胀性的各种方法,以及这些参数与片剂崩解之间的相关性。
Drug Dev Ind Pharm. 2018 Sep;44(9):1417-1425. doi: 10.1080/03639045.2018.1453519. Epub 2018 Apr 6.
9
Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.壳聚糖作为崩解剂对呋塞米片生物利用度的影响:新型制剂的体外评价与体内模拟
Pak J Pharm Sci. 2012 Oct;25(4):815-22.
10
[Preparation and evaluation of taste masked orally disintegrating tablets with granules made by the wet granulation method].[采用湿法制粒法制备颗粒剂的掩味口腔崩解片及其评价]
Yakugaku Zasshi. 2010 Dec;130(12):1737-42. doi: 10.1248/yakushi.130.1737.

引用本文的文献

1
Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, , , and study.卡格列净纳米晶舌下片在月桂酸钠渗透促进剂存在下的研制:制剂优化、特性研究、 和 研究。
Drug Deliv. 2023 Dec;30(1):2241665. doi: 10.1080/10717544.2023.2241665.
2
Evaluation of Newly Designed and Traditional Punches in Manufacturing of Scored ODTs.新型与传统冲头在刻痕口服速释片制造中的评估
Pharmaceutics. 2022 Sep 27;14(10):2054. doi: 10.3390/pharmaceutics14102054.
3
Preparation and In Vitro/In Vivo Evaluation of Orally Disintegrating/Modified-Release Praziquantel Tablets.
口服崩解/缓释吡喹酮片的制备及体外/体内评价
Pharmaceutics. 2021 Sep 27;13(10):1567. doi: 10.3390/pharmaceutics13101567.
4
Recent Formulation Advances and Therapeutic Usefulness of Orally Disintegrating Tablets (ODTs).口腔崩解片(ODTs)的最新剂型进展及治疗应用价值
Pharmacy (Basel). 2020 Oct 10;8(4):186. doi: 10.3390/pharmacy8040186.